1443211-72-0 Usage
Description
Eleclazine, also known as CAS# 1443211-72-0, is a late sodium current inhibitor and a phase II agent. It has demonstrated pre-clinical anti-ischemic and antiarrhythmic properties, making it a potential candidate for the treatment of various cardiovascular conditions.
Uses
Used in Pharmaceutical Industry:
Eleclazine is used as a therapeutic agent for the treatment of cardiovascular conditions, particularly those involving ischemia and arrhythmias. Its anti-ischemic and antiarrhythmic properties contribute to its potential effectiveness in managing and preventing complications related to these conditions.
Used in Clinical Research:
Eleclazine is used as a research compound in the development of new treatments for cardiovascular diseases. Its pre-clinical properties provide valuable insights into its potential applications and mechanisms of action, paving the way for further research and development in the field of cardiology.
Check Digit Verification of cas no
The CAS Registry Mumber 1443211-72-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,4,3,2,1 and 1 respectively; the second part has 2 digits, 7 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1443211-72:
(9*1)+(8*4)+(7*4)+(6*3)+(5*2)+(4*1)+(3*1)+(2*7)+(1*2)=120
120 % 10 = 0
So 1443211-72-0 is a valid CAS Registry Number.
1443211-72-0Relevant articles and documents
Deuterium-Substituted Oxazepin Compounds
-
, (2018/03/24)
Described are deuterium-substituted oxazepin compounds of structural Formula I, which are inhibitors/blockers of the late sodium current. Also described are pharmaceutical compositions comprising the deuterium-substituted oxazepin compounds, and methods of use thereof.
PROCESSES FOR PREPARING FUSED HETEROCYCLIC ION CHANNEL MODULATORS
-
, (2015/09/22)
The present disclosure provides processes for the preparation of a compound of formula: which is a selective late sodium current inhibitor. The disclosure also provides compounds that are synthetic intermediates.
COMPOUND AND METHODS FOR TREATING LONG QT SYNDROME
-
Paragraph 0160, (2015/02/19)
Described herein is a method of treating long QT syndrome by administration of an effective amount of a potent and selective late sodium ion channel blocker
